Postmenopausal women treated for breast cancer with insulin resistance: clinical, analytical, cross-sectional

This study aims to investigate the potential association between serum levels of cytokines, HSP60, HSP70 and IR (HOMA-IR) in postmenopausal women. We conducted a cross-sectional study involving 381 postmenopausal women, including 94 with a breast cancer diagnosis and 278 without. We analyzed anthrop...

Descripción completa

Detalles Bibliográficos
Autores: Orsatti, Claudio Lera [UNESP], Orsatti, Fabio Lera, De Souza, João Pedro Esteves Alves, de Araujo Brito Buttros, Daniel [UNESP], Nahas, Eliana Aguiar Petri [UNESP]
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:Brasil
Institución:Universidade Estadual Paulista (UNESP)
Repositorio:Repositório Institucional da UNESP
Idioma:inglés
OAI Identifier:oai:repositorio.unesp.br:11449/300129
Acceso en línea:http://dx.doi.org/10.1080/03630242.2024.2383289
https://hdl.handle.net/11449/300129
Access Level:acceso abierto
Palabra clave:Breast cancer
cardiovascular risk
HOMA-IR
insulin resistance
postmenopausal
Descripción
Sumario:This study aims to investigate the potential association between serum levels of cytokines, HSP60, HSP70 and IR (HOMA-IR) in postmenopausal women. We conducted a cross-sectional study involving 381 postmenopausal women, including 94 with a breast cancer diagnosis and 278 without. We analyzed anthropometric and laboratory measurements. Immunoassays were used to measure cytokines (TNF-α, IL-10, and IL-6) as well as heat shock proteins (HSP) 60 and 70 in the serum using the ELISA technique. Women diagnosed with breast cancer showed higher levels of HOMA-IR, IL-6, TNF, and HSP60, and lower levels of IL-10 and HSP70 compared to women without cancer. An association was found between HSP70 and HOMA-IR only in women with breast cancer (β = 0.22, p =.030; without cancer: β = 0.04, p =.404), regardless of age, waist circumference, smoking, and physical activity. No associations were observed between cytokines, HSP60, and HOMA-IR in both groups of women. HSP70 is positively associated with IR in women diagnosed with breast cancer.